Taking L-citrulline by mouth raises your blood levels of L-arginine better than taking L-arginine directly, because your body processes L-citrulline more efficiently and doesn’t break it down too...
Claim Context
Oral L-citrulline supplementation increases plasma L-arginine concentrations more effectively than direct L-arginine supplementation due to superior bioavailability and avoidance of first-pass hepatic metabolism.
The claim uses the verb 'increases' and the comparative phrase 'more effectively than', which assert a direct, certain causal relationship without hedging. The phrase 'due to' further reinforces a definitive mechanistic explanation.
“L certuline comes in. And then we'll have a look at the most popular supplement form. So it gets converted to L argonine after ingestion. And research has shown that it's actually more effective at raising L argonine levels in the blood than L argonine supplements themselves.”
Score Breakdown
No multi-axis breakdown available yet. The overall Pro / Against score above is the best signal.
- No clinical evidence is available; the score reflects mechanistic plausibility only.
Evidence from Studies
Supporting (3)
Community contributions welcome
Pharmacokinetic and pharmacodynamic properties of oral L-citrulline and L-arginine: impact on nitric oxide metabolism.
Pharmacokinetic and pharmacodynamic properties of oral L-citrulline and L-arginine: impact on nitric oxide metabolism.
Contradicting (2)
Community contributions welcome
Eight Days of L-Citrulline or L-Arginine Supplementation Did Not Improve 200-m and 100-m Swimming Time Trials
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Directly compares plasma L-arginine levels after oral L-citrulline vs. oral L-arginine in the same human participants under controlled conditions.
Healthy adult humans (n≥20) receive, in random order, a single oral dose of L-citrulline (6g) and L-arginine (6g) on separate days with a 7-day washout. Plasma L-arginine is measured at baseline and at 30, 60, 90, 120, and 180 minutes post-ingestion. Primary outcome: area under the curve (AUC) of plasma L-arginine concentration over time.
Compares the magnitude of plasma L-arginine increase between two independent groups receiving either L-citrulline or L-arginine.
Healthy adult humans (n≥40) randomly assigned to receive either 6g oral L-citrulline or 6g oral L-arginine in a single dose. Plasma L-arginine is measured at baseline and 30, 60, 90, 120, and 180 minutes. Primary outcome: peak plasma concentration (Cmax) and AUC of L-arginine. Secondary outcome: hepatic portal vein L-arginine levels (via venous sampling) to test first-pass metabolism hypothesis.
Tracks the metabolic fate of L-citrulline vs. L-arginine to confirm avoidance of first-pass metabolism and conversion efficiency.
Healthy adult humans (n≥10) receive a single oral dose of isotopically labeled L-citrulline (13C6) and separately, labeled L-arginine (13C6). Plasma and hepatic portal vein samples are collected over 4 hours. Mass spectrometry quantifies labeled compound appearance and conversion rates. Primary outcome: ratio of labeled L-arginine derived from L-citrulline vs. direct L-arginine intake.
Quantifies hepatic extraction of L-arginine vs. L-citrulline to validate the proposed mechanism.
Healthy adult humans (n≥15) receive intravenous and oral doses of L-arginine and L-citrulline on separate days. Hepatic extraction ratio is calculated from arterial-portal venous concentration differences. Primary outcome: hepatic extraction ratio of L-arginine after oral vs. IV administration, compared to L-citrulline’s hepatic extraction and subsequent conversion to L-arginine.
Correlates habitual L-citrulline intake with plasma L-arginine levels in free-living individuals.
Longitudinal cohort of 100+ healthy adults with daily dietary supplement logs and weekly plasma L-arginine measurements over 12 weeks. Participants self-report L-citrulline or L-arginine supplement use. Primary outcome: association between supplement type and plasma L-arginine concentration, adjusted for baseline levels and diet.